MSD and privately held Antelliq Group today announced that the companies have signed a definitive agreement under which MSD will acquire Antelliq from funds advised by BC Partners. Antelliq will be a wholly owned and separately operated subsidiary within the MSD Animal Health Division.
MSD Animal Health announced two significant milestones in its continued effort to expand manufacturing capacity and capabilities at its large-scale, vaccine production facility with product formulation and filling capabilities in Krems, Austria.
MSD Animal Health announced continued expansion activities of its manufacturing, packaging and warehousing facility in its Milton Keynes, United Kingdom, site, for blending and filling of poultry vaccines.
MSD Animal Health is proud to have received recognition for EXZOLT® (fluralaner) as the breakthrough of the year.
MSD Animal Health announced the launch of IDAL® 3G Twin, the first needle-free and intradermal device with two injector heads and the latest innovation in the IDAL® portfolio for swine vaccination.
MSD Animal Health participated in an interactive workshop held at the European Parliament, entitled “Looking Beyond Antibiotics: The Role of Prevention in the Fight Against Antimicrobial Resistance.”
MSD Animal Health, one of the world leaders in animal health vaccines, has begun the construction phase of a state-of-the-art manufacturing facility in Boxmeer, for sterile filling and freeze drying of vaccines.
MSD Animal Health is pleased to announce that more than two million children have received essential rabies education in the most at-risk regions of the world through the company’s partnership with Mission Rabies, a non-profit organization dedicated to eliminating rabies through canine vaccination and the education of children.
MSD Animal Health announced a significant number of abstracts to be presented at the World Buiatrics Congress in Sapporo, Japan from August 28 – September 1.
Researchers in the UK, led by The Pirbright Institute are to receive £3.1 million of investment to produce a more affordable and effective vaccine to protect animals against foot-and-mouth disease (FMD).